利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.01 秒)

    PHARMACEUTICAL COMPOSITION COMPRISING METFORMIN AND PIOGLITAZONE
    1.
    发明公开
    PHARMACEUTICAL COMPOSITION COMPRISING METFORMIN AND PIOGLITAZONE 审中-公开
    药用植物精油

    公开(公告)号：EP2611434A1

    公开(公告)日：2013-07-10

    申请号：EP11776517.2

    申请日：2011-08-31

    申请人： Lupin Limited

    发明人： KULKARNI, Shirishkumar ,  DALAL, Satish, Kumar ,  JAHAGIRDAR, Harshal ,  PATIL, Vishal

    IPC分类号： A61K31/155 ,  A61K31/4439 ,  A61K9/20

    CPC分类号： A61K31/4439 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/209 ,  A61K31/155 ,  A61K2300/00

    摘要： A pharmaceutical composition comprising metformin or pharmaceutically acceptable salts, esters, solvates, hydrates, metabolites, prodrugs or isomers thereof in extended release form and pioglitazone or pharmaceutically acceptable salts, esters, solvates, hydrates, metabolites, prodrugs or isomers thereof in immediate release form is provided. More particularly a pharmaceutical composition comprising extended release metformin core comprising metformin, extended release polymer and other pharmaceutically acceptable excipients; and immediate release pioglitazone layer comprising pioglitazone, high viscosity polymer, and other pharmaceutically acceptable excipients. Further a pharmaceutical composition comprising extended release metformin core comprising metformin, extended release polymer and other pharmaceutically acceptable excipients; and immediate release pioglitazone layer comprising pioglitazone, polyvinyl alcohol, surfactant and other pharmaceutically acceptable excipients

    摘要翻译： 一种药物组合物，其包含延时释放形式的二甲双胍或其药学上可接受的盐，酯，溶剂合物，水合物，代谢物，前药或异构体及其立即释放形式的吡格列酮或其药学上可接受的盐，酯，溶剂合物，水合物，代谢物，前药或异构体 提供。 更具体地，包含包含二甲双胍，延长释放聚合物和其它药学上可接受的赋形剂的延长释放二甲双胍核心的药物组合物; 并且立即释放吡格列酮层，其包含吡格列酮，高粘度聚合物和其它药学上可接受的赋形剂。 此外，还包含药物组合物，其包含延长释放的二甲双胍核心，其包含二甲双胍，延长释放聚合物和其它药学上可接受的赋形剂; 并且立即释放吡格列酮层，其包含吡格列酮，聚乙烯醇，表面活性剂和其它药学上可接受的赋形剂

    CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF SELECTIVE SEROTONIN REUPTAKE INHIBITOR
    4.
    发明公开
    CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF SELECTIVE SEROTONIN REUPTAKE INHIBITOR 审中-公开
    药用植物保护剂 - ZUSAMMENSETZUNGEN EINES SELEKTIVEN SEROTONINWIEDERAUFNAHMEHEMMERS

    公开(公告)号：EP2685966A1

    公开(公告)日：2014-01-22

    申请号：EP12713352.8

    申请日：2012-03-16

    申请人： Lupin Limited

    发明人： JAHAGIRDAR, Harshal ,  KATKAR, Ganesh ,  DALAL, Satish, Kumar ,  KULKARNI, Shirishkumar

    IPC分类号： A61K9/20 ,  A61K9/28 ,  A61K31/4525 ,  A61P25/24

    CPC分类号： A61K9/50 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/2846 ,  A61K31/4525

    摘要： The present invention provides a controlled release pharmaceutical composition comprising selective serotonin reuptake inhibitor and a process for preparation thereof. The controlled release pharmaceutical composition comprises: a deposit-core comprising a selective serotonin reuptake inhibitor, one or more controlled release agent(s) and one or more pharmaceutically acceptable excipient(s), a support-platform applied to the deposit-core, a controlled release coating and, an immediate release coating comprising a selective serotonin reuptake inhibitor and one or more pharmaceutically acceptable excipient(s).

    摘要翻译： 本发明提供包含选择性5-羟色胺再摄取抑制剂的控释药物组合物及其制备方法。 控释药物组合物包括：沉积物芯，其包含选择性5-羟色胺再摄取抑制剂，一种或多种控释剂和一种或多种药学上可接受的赋形剂，应用于沉积物核心的载体平台， 控制释放包衣和包含选择性5-羟色胺再摄取抑制剂和一种或多种药学上可接受的赋形剂的速释包衣。

    MODIFIED RELEASE FORMULATIONS OF HMG COA REDUCTASE INHIBITORS
    6.
    发明公开
    MODIFIED RELEASE FORMULATIONS OF HMG COA REDUCTASE INHIBITORS 审中-公开
    HMG-CoA还原酶抑制剂的配方与修饰释放

    公开(公告)号：EP2285353A1

    公开(公告)日：2011-02-23

    申请号：EP09706394.5

    申请日：2009-01-30

    申请人： Lupin Limited

    发明人： KULKARNI, Sheetal ,  DAS, Srirupa ,  DESHMUKH, Ashish, Ashokrao ,  DALAL, Satish, Kumar ,  KULKARNI, Shirishkumar

    IPC分类号： A61K9/20 ,  A61K31/22 ,  A61K31/505

    CPC分类号： A61K9/2054 ,  A61K9/205 ,  A61K31/22 ,  A61K31/505

    摘要： Modified release formulations of HMG Co-A reductase inhibitors, which provide reduced incidence of rhabdomyolysis, renal toxicity and other side effects by increasing hepatic bioavailability and decreasing systemic availability upon oral administration. The modified release pharmaceutical formulation comprises a therapeutically effective amount of HMG CoA reductase inhibitor or a pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), prodrug or metabolite thereof, one ore more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein the modified release formulation provides reduced incidence of adverse effects and improved efficacy when compared to the immediate release formulation upon oral administration.

    RIFAXIMIN READY-TO-USE SUSPENSION
    8.
    发明公开
    RIFAXIMIN READY-TO-USE SUSPENSION 有权
    RIFAXIMIN准备使用悬浮液

    公开(公告)号：EP2544660A2

    公开(公告)日：2013-01-16

    申请号：EP11717734.5

    申请日：2011-03-09

    申请人： Lupin Limited

    发明人： JAHAGIRDAR, Harshal, Anil ,  KONDA, Kishore, Kumar ,  DALAL, Satish, Kumar ,  KULKARNI, Shirishkumar

    IPC分类号： A61K9/10 ,  A61K31/437 ,  A61P31/04

    CPC分类号： A61K31/437 ,  A23L27/00 ,  A23V2002/00 ,  A61K9/10 ,  A61K31/428

    摘要： A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.

    摘要翻译： 包含分散在悬浮基质中的利福昔明和一种或多种药学上可接受的添加剂的稳定的，掩味的即用悬浮液。 还提供了制备利福昔明的稳定的，掩味的即用型悬浮液的方法，其包括以下步骤：将利福昔明与悬浮液基质混合，并通过研磨悬浮液进一步上浆利福昔明颗粒以获得均匀分散的利福昔明悬浮液 。

    MODIFIED RELEASE FORMULATION OF LACOSAMIDE
    9.
    发明公开
    MODIFIED RELEASE FORMULATION OF LACOSAMIDE 审中-公开
    紫杉醇的改性释放制剂

    公开(公告)号：EP2496220A1

    公开(公告)日：2012-09-12

    申请号：EP10790595.2

    申请日：2010-11-03

    申请人： Lupin Limited

    发明人： KULKARNI, Shirishkumar ,  DALAL, Satish, Kumar ,  JAHAGIRDAR, Harshal ,  KONDA, Kishore, Kumar

    IPC分类号： A61K9/20 ,  A61K9/50 ,  A61K47/38 ,  A61K31/00 ,  A61K47/32

    摘要： The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.

    摘要翻译： 本发明提供拉科酰胺的调节释放制剂。 包含拉考沙胺和改性释放聚合物的本发明的改良释放制剂在至少12小时的时期内提供具有最小C max至C min峰值的波谷变化的拉考沙胺的调节释放。